Long-Term Quality of Life After Total Gastrectomy Versus Ivor Lewis Esophagectomy.
Journal
World journal of surgery
ISSN: 1432-2323
Titre abrégé: World J Surg
Pays: United States
ID NLM: 7704052
Informations de publication
Date de publication:
03 2020
03 2020
Historique:
pubmed:
17
11
2019
medline:
16
12
2020
entrez:
17
11
2019
Statut:
ppublish
Résumé
There is scarce evidence on whether a total gastrectomy or an Ivor Lewis esophagectomy is preferred for gastroesophageal junction (GEJ) cancers regarding effects on morbidity, pathology, survival and health-related quality of life (HR-QoL). The aim of this study was to investigate the difference in long-term HR-QoL in patients undergoing total gastrectomy versus Ivor Lewis esophagectomy in a tertiary referral center. Patients with a follow-up of >1 year after a total gastrectomy or an Ivor Lewis esophagectomy for GEJ/cardia carcinoma completed the EORTC QLQ-C30 and EORTC QLQ-OG25 questionnaires. 'Problems with eating,' 'reflux,' and 'nausea and vomiting' were the primary HR-QoL endpoints. The secondary endpoints were the remaining HR-QoL domains, postoperative complications and pathology results. Thirty patients after gastrectomy and 71 after esophagectomy were included. Mean age was 63 years. Median follow-up was 2 years (range 12-84 months). Patients after gastrectomy reported less 'choking when swallowing' and 'coughing' (β = - 5.952, 95% CI - 9.437 to - 2.466; β = - 13.084, 95% CI - 18.525 to - 7.643). More lymph nodes were resected in esophagectomy group (p = 0.008). No difference was found in number of positive lymph nodes, R0 resection or postoperative complications. After a follow-up of >1 year 'choking when swallowing' and 'coughing' were less common after a total gastrectomy. No differences were found in postoperative complications or radicality of surgery. Based on this study, no general preference can be given to either of the procedures for GEJ cancer. These results support shared decision making when a choice between the two treatment options is possible.
Sections du résumé
BACKGROUND
There is scarce evidence on whether a total gastrectomy or an Ivor Lewis esophagectomy is preferred for gastroesophageal junction (GEJ) cancers regarding effects on morbidity, pathology, survival and health-related quality of life (HR-QoL). The aim of this study was to investigate the difference in long-term HR-QoL in patients undergoing total gastrectomy versus Ivor Lewis esophagectomy in a tertiary referral center.
METHODS
Patients with a follow-up of >1 year after a total gastrectomy or an Ivor Lewis esophagectomy for GEJ/cardia carcinoma completed the EORTC QLQ-C30 and EORTC QLQ-OG25 questionnaires. 'Problems with eating,' 'reflux,' and 'nausea and vomiting' were the primary HR-QoL endpoints. The secondary endpoints were the remaining HR-QoL domains, postoperative complications and pathology results.
RESULTS
Thirty patients after gastrectomy and 71 after esophagectomy were included. Mean age was 63 years. Median follow-up was 2 years (range 12-84 months). Patients after gastrectomy reported less 'choking when swallowing' and 'coughing' (β = - 5.952, 95% CI - 9.437 to - 2.466; β = - 13.084, 95% CI - 18.525 to - 7.643). More lymph nodes were resected in esophagectomy group (p = 0.008). No difference was found in number of positive lymph nodes, R0 resection or postoperative complications.
CONCLUSIONS
After a follow-up of >1 year 'choking when swallowing' and 'coughing' were less common after a total gastrectomy. No differences were found in postoperative complications or radicality of surgery. Based on this study, no general preference can be given to either of the procedures for GEJ cancer. These results support shared decision making when a choice between the two treatment options is possible.
Identifiants
pubmed: 31732762
doi: 10.1007/s00268-019-05281-8
pii: 10.1007/s00268-019-05281-8
doi:
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
838-848Références
J Thorac Cardiovasc Surg. 2016 May;151(5):1398-404
pubmed: 26936011
Surg Endosc. 2015 Jul;29(7):2039-45
pubmed: 25361647
Acta Oncol. 2018 Feb;57(2):195-202
pubmed: 28723307
Gastroenterol Nurs. 2002 May-Jun;25(3):120-5
pubmed: 12055380
J Natl Cancer Inst. 1993 Mar 3;85(5):365-76
pubmed: 8433390
Lancet Oncol. 2018 May;19(5):616-628
pubmed: 29650363
Br J Surg. 1996 Dec;83(12):1772-5
pubmed: 9038566
Dis Esophagus. 2018 Sep 1;31(13):1
pubmed: 30219910
J Clin Epidemiol. 2008 Apr;61(4):344-9
pubmed: 18313558
J Am Coll Surg. 2005 Aug;201(2):253-62
pubmed: 16038824
J Surg Oncol. 2002 Dec;81(4):185-94
pubmed: 12451623
Ann Surg. 2020 Feb;271(2):311-316
pubmed: 29995688
Lancet Oncol. 2015 Sep;16(9):1090-1098
pubmed: 26254683
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Ann Surg. 2000 May;231(5):635-43
pubmed: 10767784
Gastric Cancer. 2018 May;21(3):533-541
pubmed: 28852939
Eur J Surg Oncol. 2017 Oct;43(10):1962-1969
pubmed: 28797755
Eur J Cancer. 2007 Sep;43(14):2066-73
pubmed: 17702567
World J Surg. 2008 Mar;32(3):395-400
pubmed: 18188641
J Gastric Cancer. 2017 Mar;17(1):21-32
pubmed: 28337360
Dis Esophagus. 2009;22(5):422-6
pubmed: 19191862
Ann Surg. 2015 Aug;262(2):286-94
pubmed: 25607756
Br J Surg. 2008 Jan;95(1):80-4
pubmed: 17849373
BMC Cancer. 2017 Dec 28;17(1):893
pubmed: 29282088
World J Surg. 2005 Jul;29(7):841-8
pubmed: 15951920
Ann Surg. 2017 Aug;266(2):232-236
pubmed: 28187044
Gastric Cancer. 2016 Jan;19(1):312-7
pubmed: 25627475